| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
|
Oehrlein, Elisabeth M.
|
|
|
26 |
6 |
p. 791-795
|
artikel
|
| 2 |
A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021)
|
Gnanasakthy, Ari
|
|
|
26 |
6 |
p. 893-901
|
artikel
|
| 3 |
Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany
|
Schiller, Juliane
|
|
|
26 |
6 |
p. 854-864
|
artikel
|
| 4 |
Copyright/Subscription
|
|
|
|
26 |
6 |
p. v
|
artikel
|
| 5 |
Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non–Muscle Invasive Bladder Cancer
|
Joshi, Mrinmayee
|
|
|
26 |
6 |
p. 823-832
|
artikel
|
| 6 |
Cross-Attribute Level Effects Models for Modeling Modified 5-Level Version of EQ-5D Health State Values: Is Less Still More?
|
Yang, Zhihao
|
|
|
26 |
6 |
p. 865-872
|
artikel
|
| 7 |
Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma
|
Tervonen, Tommi
|
|
|
26 |
6 |
p. 909-917
|
artikel
|
| 8 |
Disability-Adjusted Life-Years for Drug Overdose Crisis and COVID-19 Are Comparable During the Two Years of Pandemic in the United States
|
Chen, Qiushi
|
|
|
26 |
6 |
p. 796-801
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
26 |
6 |
p. vi
|
artikel
|
| 10 |
Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review
|
Cadham, Christopher J.
|
|
|
26 |
6 |
p. 943-952
|
artikel
|
| 11 |
Financing and Reimbursement of Approved Advanced Therapies in Several European Countries
|
Iglesias-López, Carolina
|
|
|
26 |
6 |
p. 841-853
|
artikel
|
| 12 |
Generic Price Regulation and Drug Expenditures: Evidence From Canada
|
Li, Yang
|
|
|
26 |
6 |
p. 833-840
|
artikel
|
| 13 |
Grading Evidence to Support Legislative and Budget Proposals—Veterans Health Administration’s Key to Implementing the Evidence Act
|
Garrido, Melissa M.
|
|
|
26 |
6 |
p. 902-908
|
artikel
|
| 14 |
Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus
|
Chatzidaki, Iro
|
|
|
26 |
6 |
p. 810-822
|
artikel
|
| 15 |
Mapping Oswestry Disability Index Responses to EQ-5D-3L Utility Values: Are Cost-Utility Results Valid?
|
Ben, Ângela Jornada
|
|
|
26 |
6 |
p. 873-882
|
artikel
|
| 16 |
Measuring Financial Toxicity: A Closer Look
|
LeBlanc, Matthew R.
|
|
|
26 |
6 |
p. 953-955
|
artikel
|
| 17 |
One-Year Temporal Changes in Long COVID Prevalence and Characteristics: A Systematic Review and Meta-Analysis
|
Huang, Qiangru
|
|
|
26 |
6 |
p. 934-942
|
artikel
|
| 18 |
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
|
Cheng, Qinglu
|
|
|
26 |
6 |
p. 883-892
|
artikel
|
| 19 |
Perceived Importance of the Benefits and Harms of Colorectal Cancer Screening: A Best-Worst Scaling Study
|
Pluymen, Linda P.M.
|
|
|
26 |
6 |
p. 918-924
|
artikel
|
| 20 |
Potential Gains in Health-Adjusted Life Expectancy by Reducing Burden of Noncommunicable Diseases in 188 Countries: A Population-Based Study
|
Xi, Jun-Yan
|
|
|
26 |
6 |
p. 802-809
|
artikel
|
| 21 |
Stakeholder Engagement in Designing Attributes for a Discrete Choice Experiment With Policy Implications: An Example of 2 Swiss Studies on Healthcare Delivery
|
Föhn, Zora
|
|
|
26 |
6 |
p. 925-933
|
artikel
|
| 22 |
Table of Contents
|
|
|
|
26 |
6 |
p. i-iv
|
artikel
|
Tijdschrift beschrijving